cartitude-1: health-related qol with cilta-cel for myeloma
Published 3 years ago • 77 plays • Length 4:21Download video MP4
Download video MP3
Similar videos
-
2:09
cartitude-1: cilta-cel improves hrqol for patients with myeloma
-
1:30
cartitude-1: promising initial results of cilta-cel for myeloma
-
2:25
caritude-1: cilta-cel achieves deep and durable responses in r/r myeloma
-
2:17
cilta-cel: a paradigm shift in the treatment of multiple myeloma
-
1:25
cartitude-1: outcomes of patients with triple-class exposed multiple myeloma treated with cilta-cel
-
4:04
the future of myeloma treatment and the possibility of cure
-
1:00:30
what’s next in car t cell therapy with dr. michel sadelain
-
9:13
panel discusses use of bispecifics to treat relapsed/refractory myeloma, toxicity considerations
-
4:53
cartitude-1: latest data & crs in myeloma treated with cilta-cel
-
0:50
car-t in multiple myeloma: cilta-cel & ide-cel
-
1:38
cartitude-1 final results: pfs of cilta-cel in patients with heavily pre-treated r/r myeloma
-
5:44
cilta-cel in r/r myeloma: preliminary results from cartitude-1
-
2:25
cartitude-1 final results: cilta-cel in heavily pretreated patients with r/r myeloma
-
2:32
final results of cartitude-1: cilta-cel in heavily pretreated patients with r/r multiple myeloma
-
5:05
patient-reported outcomes in cartitude-4: cilta-cel vs soc in r/r multiple myeloma
-
1:47
cilta-cel in earlier lines of therapy for r/r multiple myeloma
-
2:31
cilta-cel achieves deep and durable responses for r/r multiple myeloma
-
2:15
updates on ide-cel and cilta-cel for myeloma
-
1:54
cilta-cel vs standard of care in functional high-risk myeloma: findings from cartitude-4
-
1:07
updated results from cartitude-1
-
2:25
cartitude-5: vrd cilta-cel or rd in newly diagnosed multiple myeloma
-
2:08
comparison of the outcomes from cartitude-1 with a real-world external cohort